Kluger, H. M., Halabi, S., Solomon, N. C., Jilaveanu, L., Zito, C., Sznol, J., … George, D. J. (2014). Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206. In Journal of Clinical Oncology (Vol. 32, pp. 4532–4532). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.4532

Kluger, Harriet M., Susan Halabi, Nicole C. Solomon, Lucia Jilaveanu, Christopher Zito, Joshua Sznol, Andrew B. Nixon, Brian I. Rini, Eric Jay Small, and Daniel J. George. “Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.” In Journal of Clinical Oncology, 32:4532–4532. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.4532.

Kluger HM, Halabi S, Solomon NC, Jilaveanu L, Zito C, Sznol J, et al. Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 4532–4532.

Kluger, Harriet M., et al. “Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 4532–4532. Crossref, doi:10.1200/jco.2014.32.15_suppl.4532.

Kluger HM, Halabi S, Solomon NC, Jilaveanu L, Zito C, Sznol J, Nixon AB, Rini BI, Small EJ, George DJ. Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 4532–4532.